6 CR, complete response; DOR, duration of response; MPT, - - PowerPoint PPT Presentation

CR, complete response; DOR, duration of response; MPT, melphalan-prednisone-thalidomide; PR, partial response; Rd, lenalidomide and low-dose dexamethasone; Rd18, Rd for 18 cycles; VGPR, very good partial response. Bahlis N et al. Assessing the Benefit of Continuous Treatment in the FIRST Trial (MM-020): Impact of Response in Patients With Transplant-Ineligible Newly Diagnosed Multiple Myeloma. EHA 2015, abstract #P277.

6

8 LEN MNTCa (n = 231) PLACEBO (n = 229)

INTERIM ANALYSIS AND UNBLINDING DEC 2009

CROSSOVER BEFORE PD ALLOWED CONTINUED TREATMENT ALL TREATMENT DISCONTINUED Jan 2011 NO CROSSOVER BEFORE PD ALLOWED LEN: 2 COURSES LEN MNTCa (n = 307) PLACEBO (n = 307) CONTINUED TREATMENT MPR: 6 COURSES

2 × 2 DESIGN LEN + DEX × 4 INDUCTION

LEN MNTCb (n = 67) NO TREATMENT (n = 68) LEN MNTCb NO TREAT MENT

ASCT

CONTINUED TREATMENT

CONTINUED TREATMENT

9

0.0 10 20 30 40 50 60 70 80 90 100 1 10 120 0.2 0.4 0.6 0.8 1.0 605 578 555 509 474 431 385 282 200 95 20 1 604 569 542 505 458 425 350 271 174 71 10 Overall Survival, mos Survival Probability Patients at risk 7-yr OS 62% 50%

LENALIDOMIDE CONTROL 0.74 (0.62-0.89) .001

• 

• 